Rare Biomarkers Specimen Collection and Stabilization Market to Reach USD 54.2 Billion, Globally, by 2031 at 8.7% CAGR: Allied Market Research
PORTLAND, Ore., Oct. 7, 2022 /PRNewswire/ -- Allied Market Research published a report, titled, "Rare Biomarkers Specimen Collection and Stabilization Market by Type (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes Vesicles), by Product (Isolation Kits and Reagent, Blood Collection Tubes, Systems), by Application (Oncology, Cardiovascular Diseases, NIPT, Transcriptomics, Pharmacogenomics, Transplant Rejection, Population Screening, Others): Global Opportunity Analysis and Industry Forecast, 2021-2031." According to the report, the global rare biomarkers specimen collection and stabilization industry generated $23.3 billion in 2021, and is expected to reach $54.2 billion by 2031, witnessing a CAGR of 8.7% from 2022 to 2031.
- According to the report, the global rare biomarkers specimen collection and stabilization industry generated $23.3 billion in 2021, and is expected to reach $54.2 billion by 2031, witnessing a CAGR of 8.7% from 2022 to 2031.
- However, the tedious and lengthy process for development of biomarkers and high cost of the development restrain the market growth.
- The Covid-19 pandemic made a positive impact on the global rare biomarkers specimen collection and stabilization market, owing to surge in prevalence of rare diseases and innovations in diagnosis of diseases using biomarkers.
- Rare biomarkers specimen collection and stabilization are utilized for determining what the coronavirus does to the body and how the body reacts on infection.